Eli Lilly and Company, Johnson & Johnson, and Merck & Co., Inc. are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares in companies that research, develop, manufacture, or sell prescription and other medicines. For investors, their value can be influenced by drug approvals, clinical-trial results, patents, competition, and healthcare regulations. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Eli Lilly and Company stock traded down $23.37 during trading hours on Wednesday, reaching $1,392.18. The company had a trading volume of 1,135,270 shares, compared to its average volume of 2,948,886. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. Eli Lilly and Company has a 12-month low of $850.51 and a 12-month high of $1,475.25. The company has a 50-day moving average price of $1,253.71 and a 200 day moving average price of $1,114.28. The firm has a market cap of $1.31 trillion, a price-to-earnings ratio of 45.21, a P/E/G ratio of 1.71 and a beta of 0.40.
Read Our Latest Research Report on LLY
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Shares of Johnson & Johnson stock traded down $2.65 on Wednesday, hitting $276.05. The stock had a trading volume of 2,019,037 shares, compared to its average volume of 7,930,541. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a one year low of $199.38 and a one year high of $290.25. The stock has a market cap of $664.54 billion, a price-to-earnings ratio of 41.83, a PEG ratio of 2.79 and a beta of 0.22. The stock's 50-day simple moving average is $267.31 and its two-hundred day simple moving average is $250.38.
Read Our Latest Research Report on JNJ
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Shares of NYSE MRK traded down $4.46 during mid-day trading on Wednesday, hitting $138.91. The stock had a trading volume of 3,590,387 shares, compared to its average volume of 10,498,482. The business has a 50 day moving average price of $145.93 and a two-hundred day moving average price of $128.97. Merck & Co., Inc. has a 1 year low of $93.90 and a 1 year high of $156.92. The company has a debt-to-equity ratio of 1.11, a quick ratio of 1.14 and a current ratio of 1.35. The firm has a market cap of $342.45 billion, a P/E ratio of 143.35, a price-to-earnings-growth ratio of 6.62 and a beta of 0.13.
Read Our Latest Research Report on MRK
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.